Option Care Health, Inc. has entered into a significant merger agreement with Onyx Bidco LLC, an investment group that includes Clayton, Dubilier & Rice and McKesson Corporation. This merger, announced on October 5, 2026, will see Option Care Health become a wholly owned subsidiary of Onyx Bidco, marking a pivotal moment for the company and the home health care services industry.
The merger is expected to enhance Option Care Health's capabilities and expand its reach in the competitive home health care market. The board of directors has unanimously approved the agreement, stating it is in the best interests of the company and its shareholders.
Background
Option Care Health, Inc. operates in the home health care services sector, classified under SIC 8082. The company trades on the Nasdaq under the ticker OPCH and is recognized as a large accelerated filer. This merger comes as part of a broader trend in the health care sector, where companies are increasingly consolidating to improve efficiencies and expand service offerings.
What the Filing Says
The SEC filing reveals that the merger agreement was finalized on October 5, 2026. The filing states, "The Company is to be acquired by an investor group comprised of affiliates of Clayton, Dubilier & Rice, LLC and McKesson Corporation." It further details that the merger will see Option Care Health continuing as the surviving corporation.
Impact
This merger could significantly impact various stakeholders, including shareholders, employees, and customers of Option Care Health. Shareholders are set to receive $32.05 per share in cash, while employees may experience changes in company structure and operations. The merger may also affect competitors in the home health care services sector, who will need to adapt to the new market dynamics.
What's Next
The filing indicates that the adoption of the merger agreement will be submitted for consideration at the Company Stockholder Meeting, where shareholders will vote on the agreement. Further details regarding the timeline for closing the merger and any regulatory approvals required were not specified in the filing.